Search research articles
Contact Us
Filters
Showing results (161-170 of 227) with videos related to
Page
of 23
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 3, 2008
A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer
Elisabeth I Heath, David W Hillman, Ulka Vaishampayan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 10, 2021
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work Group
R Donald Harvey, Kathryn F Mileham, Vishal Bhatnagar, et al.
Haematologica
|
December 24, 2013
A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms
Joshua F Zeidner, Judith E Karp, Amanda L Blackford, et al.
Frontiers in Medicine
|
June 20, 2019
Factors Affecting Combination Trial Success (FACTS): Investigator Survey Results on Early-Phase Combination Trials
Channing J Paller, Erich P Huang, Thomas Luechtefeld, et al.
Investigational New Drugs
|
January 29, 2013
A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium
Srikala S Sridhar, Mary J Mackenzie, Sebastien J Hotte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 2013
Cediranib for metastatic alveolar soft part sarcoma
Shivaani Kummar, Deborah Allen, Anne Monks, et al.
American Heart Journal
|
February 7, 2012
Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors
Richard M Steingart, George L Bakris, Helen X Chen, et al.
Cancer Chemotherapy and Pharmacology
|
September 1, 2005
Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers
Ramesh K Ramanathan, Marwan Fakih, Sridhar Mani, et al.
Leukemia & Lymphoma
|
March 12, 2014
Sunitinib malate in patients with intermediate-2 or high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia
Karen W L Yee, John M Storring, Rena Buckstein, et al.
Cancer Research Communications
|
March 27, 2023
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent <i>IDH1-</i> and <i>IDH2</i>-mutant Glioma
Kristina Fanucci, Mary Jo Pilat, Derek Shyr, et al.
Page
of 23
Search research articles
Search
Showing results (161-170 of 227) with videos related to
Sort By:
Page
of 23
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 3, 2008
A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer
Elisabeth I Heath, David W Hillman, Ulka Vaishampayan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 10, 2021
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work Group
R Donald Harvey, Kathryn F Mileham, Vishal Bhatnagar, et al.
Haematologica
|
December 24, 2013
A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms
Joshua F Zeidner, Judith E Karp, Amanda L Blackford, et al.
Frontiers in Medicine
|
June 20, 2019
Factors Affecting Combination Trial Success (FACTS): Investigator Survey Results on Early-Phase Combination Trials
Channing J Paller, Erich P Huang, Thomas Luechtefeld, et al.
Investigational New Drugs
|
January 29, 2013
A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium
Srikala S Sridhar, Mary J Mackenzie, Sebastien J Hotte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 2013
Cediranib for metastatic alveolar soft part sarcoma
Shivaani Kummar, Deborah Allen, Anne Monks, et al.
American Heart Journal
|
February 7, 2012
Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors
Richard M Steingart, George L Bakris, Helen X Chen, et al.
Cancer Chemotherapy and Pharmacology
|
September 1, 2005
Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers
Ramesh K Ramanathan, Marwan Fakih, Sridhar Mani, et al.
Leukemia & Lymphoma
|
March 12, 2014
Sunitinib malate in patients with intermediate-2 or high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia
Karen W L Yee, John M Storring, Rena Buckstein, et al.
Cancer Research Communications
|
March 27, 2023
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent <i>IDH1-</i> and <i>IDH2</i>-mutant Glioma
Kristina Fanucci, Mary Jo Pilat, Derek Shyr, et al.
Page
of 23